RESUMO
The 6,6-dibromopenam (6) was treated with CH3MgBr and carbaldehyde 5 to afford the hydroxy compound 7, which was reacted with acetic anhydride to give acetoxy compound 8. The deacetobromination of 8 with zinc and acetic acid gave 6-exomethylenepenams, E-isomer 10 and Z-isomer 9, which was oxidized to sulfone 11 by m-CPBA. The p-methoxybenzyl compounds were deprotected by AlCl3 and neutralized to give the sodium salts 12, 13 and 14.
Assuntos
Inibidores Enzimáticos/síntese química , Penicilinas/síntese química , Inibidores de beta-Lactamases , Cromatografia em Camada Fina , Inibidores Enzimáticos/química , Espectroscopia de Ressonância Magnética , Penicilinas/química , Espectrofotometria UltravioletaRESUMO
The antibacterial activity of novel beta-lactamase inhibitors, 6-exomethylene penamsulfones (CH1240, CH2140), has been compared in vivo with that of sulbactam and clavulanic acid against beta-lactamase producing strains. In vivo microbiological assessment was used as experimental mouse infection model by gram negative strains. Against Pseudomonas aeruginosa F0013, cefoperazone/CH1240 was slightly less active than sulbactam. Ampicillin/CH1240 was more active than sulbactam against Citrobacter diversus species. That of ampicillin/CH2140 was less effective than sulbactam against Escheriachia coli 3457. Especially against Citrobacter diversus 2046E, amoxicillin/CH2140 was the most potent and amoxicillin/CH1240 was slightly more active than clavulanic acid. Consequently the difference in efficacy between the drug combinations appears to be related to the degree of protection afforded the animals by the beta-lactamase inhibitors. CH1240 and CH2140 are promising new agents and should undergo further investigations.
Assuntos
Infecções Bacterianas/tratamento farmacológico , Inibidores Enzimáticos/farmacologia , Ácido Penicilânico/análogos & derivados , Triazóis/farmacologia , Inibidores de beta-Lactamases , Animais , Antibacterianos/farmacologia , Infecções Bacterianas/microbiologia , Infecções Bacterianas/prevenção & controle , Citrobacter , Ácido Clavulânico/farmacologia , Infecções por Enterobacteriaceae/tratamento farmacológico , Infecções por Enterobacteriaceae/microbiologia , Infecções por Escherichia coli/tratamento farmacológico , Infecções por Escherichia coli/microbiologia , Dose Letal Mediana , Masculino , Camundongos , Camundongos Endogâmicos ICR , Ácido Penicilânico/farmacologia , Infecções por Pseudomonas/tratamento farmacológico , Infecções por Pseudomonas/microbiologia , Sulbactam/farmacologiaRESUMO
The 6,6-dibromopenam6 was treated with CH(3)MgBr and carbaldehyde5 to afford the 6-bromo-6-(1-hydroxy-1-methyl)penicillanate7, which was reacted with acetic anhydride to give acetoxy compound8. The deacetobromination of8 with zinc and acetic acid gave 6-exomethylenpenams, Z-isomer9 and E-isomer10, which were oxidized to sulfones11 and12 by m-CPBA. The p-methoxybenzyl compounds were deprotected by AlCl(3) and neutralized to give the sodium salts13, 14, and15.
RESUMO
The(1)H-NMR signals of 2-cephems and 3-cephems have been assigned and the Nuclear Overhauser Effect (NOE) study of these compounds was undertaken.
RESUMO
A series of naltrexamine bivalent ligands, compounds with two naltrexamine pharmacophores separated by a spacer which contains a variable number of glycyl units flanking a succinyl group, were synthesized and evaluated in vivo in mice. These compounds possessed long-acting agonist and especially antagonist activities. The bivalent ligands, 2 and 3 displayed antinociceptive activity that lasted greater than 4 h. Compound 1, a bivalent ligand and 4, the monomer, antagonized the antinociceptive effect of morphine for a week after a single injection i.c.v. The long duration of action may be due to entrapment of these ligands in the central nervous system. These compounds may give future insights into the design of long-acting agonists and antagonists.
Assuntos
Naltrexona/análogos & derivados , Antagonistas de Entorpecentes/farmacologia , Entorpecentes/farmacologia , Analgésicos/farmacologia , Animais , Injeções Intraventriculares , Injeções Subcutâneas , Masculino , Camundongos , Morfina/farmacologia , Naltrexona/farmacologia , Antagonistas de Entorpecentes/administração & dosagem , Entorpecentes/administração & dosagem , Receptores Opioides/fisiologia , Receptores Opioides muRESUMO
Bivalent ligands containing the oxymorphamine or naltrexamine pharmacophores connected to spacers of varying length were synthesized and evaluated for their selectivity at mu, kappa, and delta opioid receptors. The oxymorphamine bivalent ligands (1-8) behaved as mu agonists on the electrically stimulated guinea pig ileum longitudinal muscle preparation (GPI). The spacer that conferred peak agonist activity in these series contains a total of four glycyl units (n = 2). Binding studies with guinea pig brain membranes showed a qualitatively similar profile at mu receptors as a function of spacer length. Also, delta receptor selectivity increased as the spacer was lengthened. The naltrexamine bivalent ligands (9-13) effectively antagonized the mu receptor agonist morphine in the GPI at the same optimal spacer length (n = 2) as in the agonist series. However, the peak antagonism of ethylketazocine, a kappa receptor agonist, occurred with the bivalent ligand 9 containing the shortest spacer (n = 0), and it was found that 9 is the most selective kappa antagonist in the series. While receptor binding roughly parallels that of kappa antagonist activity in the GPI, no correlation between binding and antagonist activity was observed at mu opioid receptors. The possible significance of these results is discussed.
Assuntos
Antagonistas de Entorpecentes/farmacologia , Entorpecentes/farmacologia , Receptores Opioides/efeitos dos fármacos , Animais , Cobaias , Técnicas In Vitro , Ligantes , Antagonistas de Entorpecentes/metabolismo , Entorpecentes/metabolismo , Receptores Opioides/metabolismo , Receptores Opioides delta , Receptores Opioides kappa , Receptores Opioides mu , Relação Estrutura-AtividadeAssuntos
Endorfinas/farmacologia , Animais , Encéfalo/efeitos dos fármacos , Fenômenos Químicos , Química , Cobaias , Íleo/efeitos dos fármacos , Naltrexona/análogos & derivados , Naltrexona/farmacologia , Oximorfona/análogos & derivados , Oximorfona/farmacologia , Receptores Opioides/efeitos dos fármacos , Receptores Opioides/fisiologia , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
Bivalent ligands are molecules which contain two pharmacophores linked by a connecting chain (spanner). The present report describes the use of oxymorphamine (Oxy) and naltrexamine (Nal) as the opioid agonist and antagonist pharmacophores separated by a variable length spanner composed of succinyl-bis-oligoglycine. The agonist series, [CH2CO(Gly)nOxy]2, and antagonist series, [CH2CO(Gly)nNal]2, were synthesized (n = 0-4) and tested on the electrically stimulated GPI. All of the antagonist bivalent ligands (Nal) antagonized the effects of morphine, with the greatest potency enhancement (60 x) residing with the succinyl (n = 0) congener. A dramatically different SAR profile was observed in the agonist (Oxy) series where the greatest potency enhancement (17 x) occurs when n = 2. By contrast with the antagonist series the agonist bivalent ligand with n = 0 is equipotent to its monovalent agonist analogue. The significance of these results with respect to the possibility of discrete opioid agonist and antagonist recognition sites are discussed.